Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 5961-5968

  Henry, Marine ^a   Lavigne, Rob ^b   Debarbieux, Laurent ^a  

^a INSTITUT PASTEUR   (France)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIOPHAGE; BACTERIOPHAGE CHA P1; BACTERIOPHAGE LBL3; BACTERIOPHAGE LUZ19; BACTERIOPHAGE PAK P1; BACTERIOPHAGE PAK P2; BACTERIOPHAGE PAK P3; BACTERIOPHAGE PAK P4; BACTERIOPHAGE PAK P5; BACTERIOPHAGE PHIKZ; BIOLUMINESCENCE; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; LUNG INFECTION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; ALTERNATIVE MEDICINE; ANIMAL; BAGG ALBINO MOUSE; BIOASSAY; DISEASE MODEL; GENETICS; GROWTH, DEVELOPMENT AND AGING; LUMINESCENCE; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PNEUMONIA, BACTERIAL; PREDICTIVE VALUE; PROCEDURES; PSEUDOMONAS INFECTIONS; PSEUDOMONAS PHAGE; REPORTER GENE; TREATMENT OUTCOME; VIRAL PLAQUE ASSAY; VIROLOGY;

ANIMALS; BIOLOGICAL ASSAY; COMPLEMENTARY THERAPIES; DISEASE MODELS, ANIMAL; GENES, REPORTER; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, INBRED BALB C; PNEUMONIA, BACTERIAL; PREDICTIVE VALUE OF TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS PHAGES; TREATMENT OUTCOME; VIRAL PLAQUE ASSAY;

EID: 84887439648     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01596-13     Document Type: Article

References (41)

1. Summers WC. 2001. Bacteriophage therapy. Annu. Rev. Microbiol. 55: 437-451.
2. Brussow H. 2012. What is needed for phage therapy to become a reality in Western medicine? Virology 434:138-142.
3. Deresinski S. 2009. Bacteriophage therapy: exploiting smaller fleas. Clin. Infect. Dis. 48:1096-1101.
4. Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, Abedon ST. 2010. Phage therapy in clinical practice: treatment of human infections. Curr. Pharm. Biotechnol. 11:69-86.
5. Merril CR, Scholl D, Adhya SL. 2003. The prospect for bacteriophage therapy in Western medicine. Nat. Rev. Drug Discov. 2:489-497.
6. Thiel K. 2004. Old dogma, new tricks-21st century phage therapy. Nat. Biotechnol. 22:31-36.
7. Kutateladze M, Adamia R. 2010. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 28:591-595.
8. Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Fortuna W, Letkiewicz S, Szufnarowski K, Pawelczyk Z, Rogoz P, Klak M, Wojtasik E, Gorski A. 2012. Clinical aspects of phage therapy. Adv. Virus Res. 83:73-121.
9. Jin J, Li ZJ, Wang SW, Wang SM, Huang DH, Li YH, Ma YY, Wang J, Liu F, Chen XD, Li GX, Wang XT, Wang ZQ, Zhao GQ. 2012. Isolation and characterization of ZZ1, a novel lytic phage that infects Acinetobacter baumannii clinical isolates. BMC Microbiol. 12:156. doi:10.1186/1471-2180-12-156.
10. Sepulveda-Robles O, Kameyama L, Guarneros G. 2012. High diversity and novel species of Pseudomonas aeruginosa bacteriophages. Appl. Environ. Microbiol. 78:4510-4515.
11. Loc-Carrillo C, Abedon ST. 2011. Pros and cons of phage therapy. Bacteriophage 1:111-114.
12. Raz E. 2007. Organ-specific regulation of innate immunity. Nat. Immunol. 8:3-4.
13. Bull JJ, Levin BR, DeRouin T, Walker N, Bloch CA. 2002. Dynamics of success and failure in phage and antibiotic therapy in experimental infections. BMC Microbiol. 2:35. doi:10.1186/1471-2180-2-35.
14. Bull JJ, Otto G, Molineux IJ. 2012. In vivo growth rates are poorly correlated with phage therapy success in a mouse infection model. Antimicrob. Agents Chemother. 56:949-954.
15. Levin BR, Bull JJ. 2004. Population and evolutionary dynamics of phage therapy. Nat. Rev. Microbiol. 2:166-173.
16. Payne RJ, Jansen VA. 2001. Understanding bacteriophage therapy as a density-dependent kinetic process. J. Theor. Biol. 208:37-48.
17. Payne RJ, Jansen VA. 2003. Pharmacokinetic principles of bacteriophage therapy. Clin. Pharmacokinet. 42:315-325.
18. Miller RW, Skinner EJ, Sulakvelidze A, Mathis GF, Hofacre CL. 2010. Bacteriophage therapy for control of necrotic enteritis of broiler chickens experimentally infected with Clostridium perfringens. Avian Dis. 54:33-40.
19. Saussereau E, Debarbieux L. 2012. Bacteriophages in the experimental treatment of Pseudomonas aeruginosa infections in mice. Adv. Virus Res. 83:123-141.
20. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B, Carlton R, Merril CR. 2002. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect. Immun. 70:204-210.
21. Cerveny KE, DePaola A, Duckworth DH, Gulig PA. 2002. Phage therapy of local and systemic disease caused by Vibrio vulnificus in iron-dextrantreated mice. Infect. Immun. 70:6251-6262.
22. Smith HW, Huggins MB. 1983. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J. Gen. Microbiol. 129:2659-2675.
23. Berchieri A, Jr, Lovell MA, Barrow PA. 1991. The activity in the chicken alimentary tract of bacteriophages lytic for Salmonella typhimurium. Res. Microbiol. 142:541-549.
24. Weiss M, Denou E, Bruttin A, Serra-Moreno R, Dillmann ML, Brussow H. 2009. In vivo replication of T4 and T7 bacteriophages in germ-free mice colonized with Escherichia coli. Virology 393:16-23.
25. Maura D, Galtier M, Le Bouguenec C, Debarbieux L. 2012. Virulent bacteriophages can target O104:H4 enteroaggregative Escherichia coli in the mouse intestine. Antimicrob. Agents Chemother. 56:6235-6242.
26. Tanji Y, Shimada T, Fukudomi H, Miyanaga K, Nakai Y, Unno H. 2005. Therapeutic use of phage cocktail for controlling Escherichia coli O157:H7 in gastrointestinal tract of mice. J. Biosci. Bioeng. 100:280-287.
27. Alemayehu D, Casey PG, McAuliffe O, Guinane CM, Martin JG, Shanahan F, Coffey A, Ross RP, Hill C. 2012. Bacteriophages phiMR299-2 and phiNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. mBio 3(2):e00029-12. doi:10.1128/mBio.00029-12.
28. Hoiby N. 2011. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 9:32. doi:10.1186/1741-7015-9-32.
29. Debarbieux L, Leduc D, Maura D, Morello E, Criscuolo A, Grossi O, Balloy V, Touqui L. 2010. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J. Infect. Dis. 201:1096-1104.
30. Moir DT, Ming D, Opperman T, Schweizer HP, Bowlin TL. 2007. A high-throughput, homogeneous, bioluminescent assay for Pseudomonas aeruginosa gyrase inhibitors and other DNA-damaging agents. J. Biomol. Screen. 12:855-864.
31. Toussaint B, Delic-Attree I, Vignais PM. 1993. Pseudomonas aeruginosa contains an IHF-like protein that binds to the algD promoter. Biochem. Biophys. Res. Commun. 196:416-421.
32. Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L. 2011. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One 6:e16963. doi:10.1371/journal.pone.0016963.
33. Lammens E, Ceyssens PJ, Voet M, Hertveldt K, Lavigne R, Volckaert G. 2009. Representational difference analysis (RDA) of bacteriophage genomes. J. Microbiol. Methods 77:207-213.
34. Mesyanzhinov VV, Robben J, Grymonprez B, Kostyuchenko VA, Bourkaltseva MV, Sykilinda NN, Krylov VN, Volckaert G. 2002. The genome of bacteriophage phiKZ of Pseudomonas aeruginosa. J. Mol. Biol. 317:1-19.
35. Ceyssens PJ, Miroshnikov K, Mattheus W, Krylov V, Robben J, Noben JP, Vanderschraeghe S, Sykilinda N, Kropinski AM, Volckaert G, Mesyanzhinov V, Lavigne R. 2009. Comparative analysis of the widespread and conserved PB1-like viruses infecting Pseudomonas aeruginosa. Environ. Microbiol. 11:2874-2883.
36. Boulanger P. 2009. Purification of bacteriophages and SDS-PAGE analysis of phage structural proteins from ghost particles. Methods Mol. Biol. 502:227-238.
37. Maura D, Morello E, du Merle L, Bomme P, Le Bouguenec C, Debarbieux L. 2012. Intestinal colonization by enteroaggregative Escherichia coli supports long-term bacteriophage replication in mice. Environ. Microbiol. 14:1844-1854.
38. Cairns BJ, Timms AR, Jansen VAA, Connerton IF, Payne RJH. 2009. Quantitative models of in vitro bacteriophage-host dynamics and their application to phage therapy. PLoS Pathog. 5:e1000253. doi:10.1371/journal.ppat. 1000253.
39. Loc Carrillo C, Atterbury RJ, el-Shibiny A, Connerton PL, Dillon E, Scott A, Connerton IF. 2005. Bacteriophage therapy to reduce Campylobacter jejuni colonization of broiler chickens. Appl. Environ. Microbiol. 71:6554-6563.
40. Pirnay JP, De Vos D, Verbeken G, Merabishvili M, Chanishvili N, Vaneechoutte M, Zizi M, Laire G, Lavigne R, Huys I, Van den Mooter G, Buckling A, Debarbieux L, Pouillot F, Azeredo J, Kutter E, Dublanchet A, Gorski A, Adamia R. 2011. The phage therapy paradigm: pret-a-porter or sur-mesure? Pharm. Res. 28:934-937.
41. Chan BK, Abedon ST, Loc-Carrillo C. 2013. Phage cocktails and the future of phage therapy. Future Microbiol. 8:769-783.